Agencies, 20 July: COVID-19 vaccine nemide suru trial data toh Oxford University aro AstraZeneca melikena bonaishe. Editor in Chief of UK based medical Journal ‘The Lancet’ koise, “Etu toh “safe, well-tolerated aro immunogenic” ase.
Science journal The Lancet laga editor, Richard Horton koise, “Phase 1/2 Oxford COVID-19 vaccine trial toh etiya publish korise. Vaccine toh safe, well-tolerated, aro immunogenic ase. Etu result toh ektum encourage kora laga ase. Pedro Folegatti aro colleagues ke congratulations”.
Add Comment